替莫唑胺
医学
放射治疗
垂体瘤
化疗
肿瘤科
内科学
人口
环境卫生
作者
Andrew Lin,Mark T.A. Donoghue,Sharon L. Wardlaw,T. Jonathan Yang,Lisa Bodei,Viviane Tabar,Eliza B. Geer
标识
DOI:10.1210/clinem/dgaa649
摘要
A small subset of pituitary adenomas grows despite maximal treatment with standard therapies; namely, surgery and radiotherapy. These aggressive tumors demonstrate 2 patterns of growth: they may be locally aggressive or metastasize distantly, either hematogenously or through the spinal fluid. Further surgery and radiotherapy may be helpful for palliation of symptoms, but they are rarely definitive in the management of these malignant tumors. The only chemotherapy with established activity in the treatment of pituitary tumors is the alkylating agent temozolomide. At most, 50% of patients exhibit an objective response to temozolomide and the median time to progression is short; thus, there remains a significant unmet need for effective treatments within this patient population. Several targeted agents have reported activity in this tumor type-including small molecule inhibitors, checkpoint inhibitors, and other biologics-but remain investigational at this time.
科研通智能强力驱动
Strongly Powered by AbleSci AI